From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Axicabtagene Ciloleucel Demonstrates Improvement Across Multiple Endpoints in Relapsed or Refractory Follicular Lymphoma

In the treatment of relapsed/refractory follicular lymphoma, a comparison of data from the ZUMA-5 trial with those of the external control cohort of the SCHOLAR-5 trial showed substantial improvement in all clinical endpoints with axicabtagene ciloleucel. John G. Gribben, DSc, FRCP, FRCPath, FMedSci, and colleagues reported these findings in a late-breaking abstract at the European Hematology Association 2021 Virtual Congress.

The ASCO Post
Advertisement
News & Literature Highlights
Advertisement
Advertisement